Stanford

Bita Fakhri, MD, MPH

Associate Professor of Medicine (Hematology)

Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Hematology Division**

  269 Campus Dr Rm 1155

  MC 5156

  Stanford, CA 94305

  Tel (650) 723-9729 **Fax** (650) 724-5203

Bio

BIO

Dr. Bita Fakhri is an Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, Richter's syndrome, and other hematologic malignancies.

As a clinical scientist, Dr. Fakhri is dedicated to patient care, trainee education, and the development of novel therapies for individuals with CLL/SLL. She has co-authored numerous publications focusing on CLL, targeted therapies, and cellular therapies in hematologic malignancies.

Dr. Fakhri currently serves as Director of the CLL Clinical Trial Portfolio at Stanford. In addition, she is actively involved in building infrastructure to expand access to clinical trials and promote equity in care for underserved and marginalized populations across the Stanford catchment area.

CLINICAL FOCUS

- Hematology
- clinical trials
- CLL/SLL
- hairy cell leukemia
- PLL
- indolent lymphomas

ACADEMIC APPOINTMENTS

- Associate Prof-Univ Med Line, Medicine - Hematology

ADMINISTRATIVE APPOINTMENTS

- Parberry Faculty Scholar, School of Medicine, (2026- present)

HONORS AND AWARDS

- Junior Faculty Career Development Award, University of California, San Francisco (2020)
- Division of Hematology and Oncology Annual Teaching Award, University of California, San Francisco (2021)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Editorial Board, Blood (ASH Publications) (2023 - present)
- Panel Member, CLL and Hairy Cell Leukemia Guidelines Committee, National Comprehensive Cancer Network (2022 - 2024)
- Panel Member, B Cell Lymphomas Guidelines Committee, National Comprehensive Cancer Network (2019 - 2022)

PROFESSIONAL EDUCATION

- Board Certification, American Board of Internal Medicine , Medical Oncology (2018)
- Board Certification, American Board of Internal Medicine , Hematology (2018)
- Board Certification, American Board of Internal Medicine , Internal Medicine (2015)
- Certificate, Washington University School of Medicine , Clinical Investigation (2018)
- Fellowship, Washington University School of Medicine , Hematology and Medical Oncology (2018)
- Residency, Boston University Medical Center , Internal Medicine (2015)
- MPH, Yale School of Public Health , Epidemiology and Biostatistics (2011)
- MD, Iran University of Medical Sciences , Medicine (2009)

LINKS

- Pioneering New CLL Treatments for All: https://domannualreports.stanford.edu/pioneering-new-cll-treatments-for-all-bita-fakhris-innovative-approach/

Research & Scholarship

CLINICAL TRIALS

- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia, Recruiting
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML, Not Recruiting
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome, Not Recruiting
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL), Not Recruiting
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies, Not Recruiting
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL), Not Recruiting

Publications

PUBLICATIONS

- **COST-SAVINGS ASSOCIATED WITH VENETOCLAX-OBINUTUZUMAB VERSUS COVALENT BRUTON'S TYROSINE KINASE INHIBITOR IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD STUDY**

  Skarbnik, A. P., Emechebe, N., Fakhri, B., Houshyar, S., Manzoor, B. S., Ghosh, N., Shadman, M., Okoye, G., Li, S. S., Barr, P. M.

  ELSEVIER SCIENCE INC.2026: S110-S111

- **Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.** *The Lancet. Haematology*

  Palomba, M. L., Patel, M. R., Eyre, T. A., Jurczak, W., Lewis, D., Gastinne, T., Ma, S., Cohen, J. B., Patel, K., Brown, J. R., Scarfò, L., Munir, T., Lech-Maranda, et al

2026; 13 (5): e284-e296

- **Treatment effectiveness in CLL patients receiving venetoclax-based therapy after progression on a covalent BTKi**
  Fleury, I., Hill, B., Eyre, T., Ujjani, C., Manzoor, B., Brown, J., Tuncer, H., Lamanna, N., Coombs, C., Ghosh, N., Leslie, L., Roeker, L., Martinez-Calle, et al
  WILEY.2026: S259

- **Real-world effectiveness of venetoclax-obinutuzumab versus second-generation Bruton tyrosine kinase inhibitors in frontline chronic lymphocytic leukemia**
  Fakhri, B., Skarbnik, A., Shadman, M., Emechebe, N., Manzoor, B., Ghosh, N., Lima, R., Mbous, Y., Houshyar, S., Sinai, W., Li, S., Kelly, J., Barr, et al
  WILEY.2026: S65

- **Favorable Real-World Outcomes of Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia**
  Huang, J. J., Voutsinas, J. M., Khaire, N. S., Pizzuti, V., Shune, L., Lei, M., Fonseca, R., Ammad-Ud-Din, M., Skarbnik, A., Mian, A., Bharadwaj, S., Alsouqi, A., Wankel, et al
  ELSEVIER SCIENCE INC.2026: S51-S52

- **Pirtobrutinib in Post-cBTKi chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Phase 1/2 BRUIN Study with more than 5 years Follow-Up (Final Update)**
  Wierda, W., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Tessoulin, B., Shah, et al
  KARGER.2026: 266

- **Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.** *Blood*
  Sekrecki, M., Sekrecka, A., Lattupally, R. R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B. A., Pineda, J. M., Cao, X., Nguyen, L., Chen, et al
  2026

- **Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.** *Blood advances*
  Patel, K., Vose, J. M., Nasta, S. D., Brown, J. R., Maddocks, K. J., Woyach, J. A., Shah, N. N., Fakhri, B., Tessoulin, B., Ma, S., Jagadeesh, D., Lech-Maranda, E., Coombs, et al
  2026

- **Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia**
  Huang, J., Voutsinas, J., Khaire, N., Pizzuti, V., Shune, L., Lei, M., Fonseca, R., Din, M., Skarbnik, A., Mian, A., Bharadwaj, S., Alsougi, A., Wankel, et al
  ELSEVIER.2025: 798-799

- **Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.** *British journal of haematology*
  Fakhri, B., Lattupally, R., Sint, K., Stehr, H., Menke, J. R., Conte, M., Shanafelt, T., Lu, S. X.
  2025

- **Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience**
  Jensen, C., Shadman, M., Chang, A., Lamanna, N., Manzoor, B., Ujjani, C., Stephens, D., Sinai, W., Hill, B., Brown, J., Tuncer, H., Davids, M. S., Eyre, et al
  ELSEVIER.2025: 3885-3886

- **Real-world discontinuation of cBTKi-based treatments in with CLL/SLL in the United States**
  Fakhri, B., Winfree, K., Bhandari, N., Xu, Z., Abada, P., Abhyankar, S., Ahn, I.
  ELSEVIER.2025: 8030-8031

- **Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study**
  Wang, M., Cohen, J., Shah, N., Jurczak, W., Zinzani, P., Cheah, C., Ujjani, C., Koh, Y., Kim, W., Nasta, S., Flinn, I., Tessoulin, B., Ma, et al
  ELSEVIER.2025: 665-666

- **Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study**
  Cheah, C., Patel, M., Eyre, T., Jurczak, W., Lewis, D., Gastinne, T., Ma, S., Cohen, J., Patel, K., Brown, J., Scarfo, L., Munir, T., Lech-Maranda, et al
  ELSEVIER.2025: 226-227

- **Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16**
  Sekrecki, M., Sekrecka, A., Lattupally, R., Le, K., Cao, X., Chen, V., Zhuang, Z., Dwyer, B., Zhou, C., Tiwari, C., Gabel, A., Kim, W., Stanley, et al
  ELSEVIER.2025: 1474-1475

- **Updated results from a Phase II study of minimal residual disease-guided venetoclax plus obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia**
  Thompson, M., Mato, A., Zelenetz, A., Park, J., Geyer, M., Derkach, A., Nemirovsky, D., Stephens, D., Coombs, C., Islam, P., Jensen, C., Falchi, L., Palomba, et al
  ELSEVIER.2025: 3902-3903

- **Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up**
  Wierda, W., Brown, J., Ghia, P., Roeker, L., Patel, K., Eyre, T., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C., Seymour, J., Tessoulin, B., Shah, et al
  ELSEVIER.2025: 2115-2116

- **Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis**
  Bhaskar, A., Oh, A., Shomali, W., Mannis, G., Liedtke, M., Gotlib, J., Shanafelt, T., Fakhri, B.
  ELSEVIER.2025: 6308

- **Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study.** *Blood advances*
  Shah, N. N., Zinzani, P. L., Wang, M. L., Nasta, S. D., Lech-Maranda, E., Ogawa, Y., Fakhri, B., Kuss, B. J., Miyashita, K., Patel, K., Coombs, C. C., Ma, S., Patel, et al
  2025

- **Epcoritamab Monotherapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: EPCORE CLL-1 Expansion and Optimization Data**
  Robson, E., Danilov, A., Fakhri, B., Awan, F., Bentzen, H., Eradat, H., Niemann, C., Offner, F., Poulsen, C., Hoyer, T., Bellido, M., Roos-Weil, D., Ferrajoli, et al
  WILEY.2025

- **Consensus in CLL: global needs matter.** *Blood advances*
  Shadman, M., Fakhri, B., Jain, N.
  2025; 9 (5): 1210-1212

- **Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.** *American journal of hematology*
  Ghosh, N., Eyre, T. A., Brown, J. R., Lamanna, N., Manzoor, B. S., Coombs, C. C., Tuncer, H. H., Ujjani, C., Leslie, L. A., Roeker, L. E., Davids, M. S., Rhodes, J. M., Skarbnik, et al
  2024

- **Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study**
  Lamanna, N., Brown, J. R., Ujjani, C. S., Eyre, T. A., Manzoor, B., Ghosh, N., Roeker, L., Davids, M. S., Coombs, C. C., Skarbnik, A. P., Hill, B. T., Tuncer, H. H., Leslie, et al
  ELSEVIER.2024: 4625-4628

- **Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1**
  Danilov, A., Fakhri, B., Awan, F. T., Bentzen, H., Eradat, H. A., Niemann, C., Offner, F., Poulsen, C., Hoeyer, T., Bellido, M., Weil, D., Ferrajoli, A., Thompson, et al
  ELSEVIER.2024: 883-885

- **Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)**
  Roeker, L., Mato, A. R., Zelenetz, A. D., Park, J. H., Geyer, M., Derkach, A., Nemirovsky, D., Islam, P., Falchi, L., Palomba, M., Kumar, A., Salles, G., Lue, et al
  ELSEVIER.2024: 1011-1012

- **Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.** *Haematologica*
  Shah, N. N., Wang, M., Roeker, L. E., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Ghia, P., Lamanna, N., Hoffmann, et al

2024

- **Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.** *EJHaem*
  Lamanna, N., Tam, C. S., Woyach, J. A., Alencar, A. J., Palomba, M. L., Zinzani, P. L., Flinn, I. W., Fakhri, B., Cohen, J. B., Kontos, A., Konig, H., Ruppert, A. S., Chatterjee, et al
  2024; 5 (5): 929-939

- **Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies**
  Tuncer, H. H., Ghosh, N., Fleury, I., Leslie, L. A., Manzoor, B. S., Lamanna, N., Eyre, T. A., Hill, B. T., Brown, J. R., Sinai, W., Coombs, C. C., Ujjani, C., Roeker, et al
  CIG MEDIA GROUP, LP.2024: S357-S358

- **Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.** *British journal of haematology*
  Fakhri, B., Wang, V., Perez-Burbano, G., Wall, A., Mandrekar, S., Parikh, S. A., Woyach, J., Shanafelt, T.
  2024

- **Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.** *British journal of haematology*
  Ghosh, N., Manzoor, B. S., Fakhri, B., Emechebe, N., Alhasani, H., Skarbnik, A., Jawaid, D., Shadman, M.
  2024

- **Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.** *JCO oncology practice*
  Fakhri, B., Emechebe, N., Manzoor, B. S., Jawaid, D., Alhasani, H., Edwards, M., Tuncer, H. H.
  2024: OP2300630

- **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Wierda, W. G., Brown, J., Abramson, J. S., Awan, F., Bilgrami, S. F., Bociek, G., Brander, D., Cortese, M., Cripe, L., Davis, R. S., Eradat, H., Fakhri, B., Fletcher, et al
  2024; 22 (3): 175-204

- **Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.** *Blood advances*
  Samples, L., Voutsinas, J. M., Fakhri, B., Khajavian, S., Spurgeon, S. E., Stephens, D. M., Skarbnik, A. P., Mato, A. R., Broome, C., Gopal, A. K., Smith, S. D., Lynch, R. C., Rainey, et al
  2024

- **Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Updated Safety and Efficacy including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study**
  Cohen, J. B., Shah, N. N., Jurczak, W., Zinzani, P., Cheah, C. Y., Eyre, T. A., Ujjani, C. S., Koh, Y., Kim, W., Nasta, S. D., Flinn, I., Tessoulin, B., Shuo, et al
  KARGER.2024: 119-120

- **Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the PostVenetoclax Era**
  St Martin, E. C., Schwede, M., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Zhang, T. Y., Mannis, G.
  AMER SOC HEMATOLOGY.2023

- **Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study**
  Shah, N. N., Zinzani, P., Wang, M. L., Nasta, S. D., Lech-Maranda, E., Ogawa, Y., Fakhri, B., Kuss, B., Miyashita, K., Patel, K., Coombs, C. C., Ma, S., Patel, et al
  AMER SOC HEMATOLOGY.2023

- **A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation**
  Roeker, L. E., Zelenetz, A. D., Park, J. H., Derkach, A., Geyer, M., Islam, P., Falchi, L., Palomba, M., Kumar, A., Salles, G., Lue, J., Goldberg, A. D., Fakhri, et al
  AMER SOC HEMATOLOGY.2023

- **Pirtobrutinib in Post-cBTKi CLL/SLL: #30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study**
  Woyach, J. A., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Seymour, J. F., Tessoulin, B., Shah, et al
  AMER SOC HEMATOLOGY.2023

- **Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort**
  Cheung, E., Schumann, C., Zhang, T. Y., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Mannis, G.
  AMER SOC HEMATOLOGY.2023

- **Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study**
  Patel, K., Vose, J. M., Nasta, S. D., Brown, J. R., Maddocks, K. J., Woyach, J. A., Shah, N. N., Fakhri, B., Tessoulin, B., Ma, S., Jagadeesh, D., Lech-Maranda, E., Coombs, et al
  AMER SOC HEMATOLOGY.2023

- **Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study**
  Cohen, J. B., Shah, N. N., Jurczak, W., Zinzani, P., Cheah, C. Y., Eyre, T. A., Ujjani, C. S., Koh, Y., Kim, W., Nasta, S. D., Flinn, I. W., Tessoulin, B., Ma, et al
  AMER SOC HEMATOLOGY.2023

- **Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.** *The New England journal of medicine*
  Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Shah, N. N., Coombs, C. C., Ujjani, et al
  2023; 389 (1): 33-44

- **Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.** *European journal of nuclear medicine and molecular imaging*
  Banerjee, R., Wang, V., Huang, C. Y., Pandita, D., Leonard, M. K., LaRue, S., Ahmadi, M., Kaplan, L., Ai, W. Z., Fakhri, B., Spinner, M., Seshadri, M. R., Pampaloni, et al
  2023

- **Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.** *Lancet (London, England)*
  Siddiqi, T., Maloney, D. G., Kenderian, S. S., Brander, D. M., Dorritie, K., Soumerai, J., Riedell, P. A., Shah, N. N., Nath, R., Fakhri, B., Stephens, D. M., Ma, S., Feldman, et al
  2023

- **Value of embedded palliative care: outpatient palliative care and healthcare utilization for hematologic malignancies.** *Blood advances*
  Tsang, M., Bischoff, K. E., Schoenbeck, K. L., Berry, K., O'Riordan, D., Fakhri, B., Wong, S. W., Shah, N., Olin, R. L., Andreadis, C., Vieaux, J., Cohen, E., Shepard Lopez, et al
  2023

- **SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.** *Clinical lymphoma, myeloma & leukemia*
  Fakhri, B., Danilov, A.
  2023

- **Copy Number Loss at Chromosome 14q11.2 Correlates With the Proportion of T Cells in Biopsies and Helps Identify T-Cell Neoplasms.** *Archives of pathology & laboratory medicine*
  Saglam, A., Singh, K., Kumar, J., Gollapudi, S., Mukherjee, S., Singh, A., Butzmann, A., Kaplan, L., Andreadis, C., Ai, W. Z., Fakhri, B., Rajkovic, A., Wen, et al
  2022

- **Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation**
  Thompson, M. C., Coombs, C. C., Roeker, L. E., Jensen, J. L., Shah, N. N., Luo, T., Patel, K., Bailey, N., Fakhri, B., Eyre, T. A., Ghione, P., Rhodes, J. M., Zelenetz, et al
  AMER SOC HEMATOLOGY.2022: 9885-9888

- **MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study.** *Clinical lymphoma, myeloma & leukemia*

Cohen, J. B., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Coombs, C. C., Flinn, I. W., Lewis, et al
2022; 22 Suppl 2: S394-S395

- **CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study.** *Clinical lymphoma, myeloma & leukemia*
  Coombs, C. C., Pagel, J. M., Shah, N. N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, et al
  2022; 22 Suppl 2: S268-S269

- **Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.** *Leukemia & lymphoma*
  Guan, T., Lo, M., Young, R., Ai, W., Boulbol, F., Mouanoutoua, H., Chu, R., Andreadis, C., Kaplan, L., Abdulhaq, H., Fakhri, B.
  2022: 1-4

- **Embedded outpatient palliative care for hematologic malignancies: Referral patterns and health care utilization.**
  Tsang, M., Bischoff, K. E., Schoenbeck, K. L., Berry, K., O'Riordan, D., Fakhri, B., Wong, S., Shah, N., Cohen, E., Lopez, N., Mannis, G. N., Rabow, M. W.
  LIPPINCOTT WILLIAMS & WILKINS.2022

- **Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.** *Leukemia & lymphoma*
  Banerjee, R., Fakhri, B., Shah, N.
  2021; 62 (11): 2600-2611

- **Current and emerging treatment options in primary mediastinal B-cell lymphoma.** *Therapeutic advances in hematology*
  Fakhri, B., Ai, W.
  2021; 12: 20406207211048959

- **Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.** *Leukemia & lymphoma*
  Fakhri, B., Yilmaz, E., Gao, F., Ambinder, R. F., Jones, R., Bartlett, N. L., Cashen, A., Wagner-Johnston, N.
  2021; 62 (10): 2408-2415

- **Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.** *Leukemia & lymphoma*
  Parks, A. L., Kambhampati, S., Fakhri, B., Andreadis, C., Gray, L., Wong, S. W., Shah, N., Fang, M. C.
  2021; 62 (4): 1003-1006

- **Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.** *Clinical lymphoma, myeloma & leukemia*
  Kambhampati, S., Hunter, B., Varnavski, A., Fakhri, B., Kaplan, L., Ai, W. Z., Pampaloni, M., Huang, C. Y., Martin, T., Damon, L., Andreadis, C. B.
  2021; 21 (4): 246-256.e2

- **Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.** *Lancet (London, England)*
  Mato, A. R., Shah, N. N., Jurczak, W., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., Alencar, A., Lech-Maranda, E., Wierda, et al
  2021; 397 (10277): 892-901

- **Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.** *Clinical lymphoma, myeloma & leukemia*
  Kambhampati, S., Fakhri, B., Ai, W. Z., Kaplan, L. D., Tuscano, J. M., Wieduwilt, M. J., Sudhindra, A., Cavallone, E., Reiner, J., Aoun, C., Castillo, M., Martinelli, M., Ta, et al
  2021; 21 (3): 139-146

- **A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.** *Clinical lymphoma, myeloma & leukemia*
  Kennedy, V. E., Ruiz-Cordero, R., Jangam, D., Wen, K. W., Dunavin, N., Ohgami, R. S., Bhargava, P., Ai, W., Fakhri, B.
  2021

- **The role of acalabrutinib in adults with chronic lymphocytic leukemia.** *Therapeutic advances in hematology*
  Fakhri, B., Andreadis, C.
  2021; 12: 2040620721990553

- **NCCN Guidelines Insights: B-Cell Lymphomas, Version 5.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., De Vos, S., Dholaria, B., Fakhri, B., Fayad, et al
  2021; 19 (11): 1218-1230

- **Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Mato, A. R., Roeker, L. E., Jacobs, R., Hill, B. T., Lamanna, N., Brander, D., Shadman, M., Ujjani, C. S., Yazdy, M. S., Perini, G. F., Pinilla-Ibarz, J. A., Barrientos, J., Skarbnik, et al
  2020; 26 (14): 3589-3596

- **Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series.** *Clinical lymphoma, myeloma & leukemia*
  Kambhampati, S., Gray, L., Fakhri, B., Lo, M., Vu, K., Arora, S., Kaplan, L., Ai, W. Z., Andreadis, C.
  2020; 20 (3): e118-e123

- **Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.** *Cancer*
  Fakhri, B., Fiala, M. A., Shah, N., Vij, R., Wildes, T. M.
  2020; 126 (4): 808-813

- **Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.** *Cancer*
  Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., Mier Hicks, A., Curry, M., Wagner-Johnston, N. D., Karmali, R., Behdad, A., Fakhri, B., Kahl, et al
  2020; 126 (2): 293-303

- **Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.** *Annals of diagnostic pathology*
  Wen, K. W., Fakhri, B. n., Menke, J. n., Ruiz-Cordero, R. n., Gill, R. M., Ohgami, R. S.
  2020; 46: 151534

- **CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.** *Oncology (Williston Park, N.Y.)*
  Fakhri, B., Andreadis, C.
  2019; 33 (11)

- **Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome.** *Clinical lymphoma, myeloma & leukemia*
  Fakhri, B., Cashen, A. F., Duncavage, E. J., Watkins, M. P., Wartman, L. D., Bartlett, N. L.
  2019; 19 (9): e532-e535

- **Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.** *British journal of haematology*
  Hill, B. T., Nastoupil, L., Winter, A. M., Becnel, M. R., Cerhan, J. R., Habermann, T. M., Link, B. K., Maurer, M. J., Fakhri, B., Reddy, P., Smith, S. D., Mukhija, D., Jagadeesh, et al
  2019; 184 (4): 524-535

- **Bones in Multiple Myeloma: Imaging and Therapy.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
  Zamagni, E., Cavo, M., Fakhri, B., Vij, R., Roodman, D.
  2018; 38: 638-646

- **Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.** *Clinical lymphoma, myeloma & leukemia*
  Fakhri, B., Fiala, M. A., Tuchman, S. A., Wildes, T. M.
  2018; 18 (3): 219-224

- **Current and emerging treatment options for mantle cell lymphoma.** *Therapeutic advances in hematology*
  Fakhri, B., Kahl, B.
  2017; 8 (8): 223-234

- **Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature.** *Journal of gastrointestinal oncology*

Fakhri, B., Lim, K. H.
2017; 8 (3): 379-386

- **Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML.** *Case reports in hematology*
  Fakhri, B., Fiala, M., Slade, M., Westervelt, P., Ghobadi, A.
  2017; 2017: 3728429
- **Halfway there: the past, present and future of haploidentical transplantation.** *Bone marrow transplantation*
  Slade, M., Fakhri, B., Savani, B. N., Romee, R.
  2017; 52 (1): 1-6
- **Clonal Evolution in Multiple Myeloma.** *Clinical lymphoma, myeloma & leukemia*
  Fakhri, B., Vij, R.
  2016; 16 Suppl: S130-4